Emilia Lupulescu

TL;DR: These global influenza-associated respiratory mortality estimates are higher than previously reported, suggesting that previous estimates might have underestimated disease burden.

TL;DR: Characteristics of SARI patients are described and results on risk factors for a severe outcome in influenza-positive SARI cases have identified several risk groups, especially relevant in the light of an overall low vaccination uptake and antiviral use in Eastern Europe.

TL;DR: Results from a European multicentre case-control study reported by Marta Valenciano and colleagues suggest good protection by the pandemic monovalent H 1N1 vaccine against pH1N1 and no effect of the 2009–2010 seasonal influenza vaccine on H1n1.

TL;DR: To assess if vaccination campaign strategies need revising more evidence on VE by time since vaccination is urgently needed, combined I-MOVE data from 2010/11 to 2014/15 is studied.

TL;DR: Within I-MOVE (European programme to monitor seasonal and pandemic influenza vaccine effectiveness (IVE) five countries conducted IVE pilot case-control studies in 2008-9, a pooled analysis was conducted to obtain early IVE estimates in groups targeted for pandemic H1N1 influenza vaccination.